These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23927371)

  • 1. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
    Evens AM; Rosen ST; Helenowski I; Kline J; Larsen A; Colvin J; Winter JN; van Besien KM; Gordon LI; Smith SM
    Br J Haematol; 2013 Oct; 163(1):55-61. PubMed ID: 23927371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
    Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
    J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
    Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
    Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
    Kouroukis CT; Fernandez LA; Crump M; Gascoyne RD; Chua NS; Buckstein R; Turner R; Assouline S; Klasa RJ; Walsh W; Powers J; Eisenhauer E
    Leuk Lymphoma; 2011 Mar; 52(3):394-9. PubMed ID: 21323520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Balzarotti M; Magagnoli M; Canales MÁ; Corradini P; Grande C; Sancho JM; Zaja F; Quinson AM; Belsack V; Maier D; Carlo-Stella C
    Invest New Drugs; 2021 Aug; 39(4):1028-1035. PubMed ID: 33523334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.
    Reiman T; Savage KJ; Crump M; Cheung MC; MacDonald D; Buckstein R; Couban S; Piliotis E; Imrie K; Spaner D; Shivakumar S; Kuruvilla J; Villa D; Shepherd LE; Skamene T; Winch C; Chen BE; Hay AE
    Leuk Lymphoma; 2019 Apr; 60(4):912-919. PubMed ID: 30301414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
    Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
    Mahadevan D; Unger JM; Spier CM; Persky DO; Young F; LeBlanc M; Fisher RI; Miller TP
    Cancer; 2013 Jan; 119(2):371-9. PubMed ID: 22833464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.
    Barton S; Hawkes EA; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Attygalle A; Horwich A; Potter M; Ethell M; Dearden C; Gleeson M; Chau I
    Eur J Haematol; 2015 Mar; 94(3):219-26. PubMed ID: 25039915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
    Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y
    Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma.
    Yao YY; Tang Y; Zhu Q; Zhuang Y; Cheng YM; Wang L; Zou LF
    Leuk Lymphoma; 2013 Jun; 54(6):1194-200. PubMed ID: 23061678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.
    Hapgood G; Stone JM; Zannino D; George A; Marlton P; Prince HM; Hui CH; Prosser I; Lewis ID; Bradstock K; Seymour JF;
    Leuk Lymphoma; 2019 Apr; 60(4):904-911. PubMed ID: 30547695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
    Shen QD; Wang L; Zhu HY; Liang JH; Xia Y; Wu JZ; Fan L; Li JY; Xu W
    J Cancer; 2021; 12(1):163-169. PubMed ID: 33391412
    [No Abstract]   [Full Text] [Related]  

  • 14. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.
    Forero-Torres A; Bartlett N; Beaven A; Myint H; Nasta S; Northfelt DW; Whiting NC; Drachman JG; Lobuglio AF; Moskowitz CH
    Leuk Lymphoma; 2013 Feb; 54(2):277-83. PubMed ID: 22775314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Czuczman MS; Trněný M; Davies A; Rule S; Linton KM; Wagner-Johnston N; Gascoyne RD; Slack GW; Brousset P; Eberhard DA; Hernandez-Ilizaliturri FJ; Salles G; Witzig TE; Zinzani PL; Wright GW; Staudt LM; Yang Y; Williams PM; Lih CJ; Russo J; Thakurta A; Hagner P; Fustier P; Song D; Lewis ID
    Clin Cancer Res; 2017 Aug; 23(15):4127-4137. PubMed ID: 28381416
    [No Abstract]   [Full Text] [Related]  

  • 16. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Moccia AA; Hitz F; Hoskins P; Klasa R; Power MM; Savage KJ; Shenkier T; Shepherd JD; Slack GW; Song KW; Gascoyne RD; Connors JM; Sehn LH
    Leuk Lymphoma; 2017 Feb; 58(2):324-332. PubMed ID: 27347845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
    Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
    Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
    Mendler JH; Kelly J; Voci S; Marquis D; Rich L; Rossi RM; Bernstein SH; Jordan CT; Liesveld J; Fisher RI; Friedberg JW
    Ann Oncol; 2008 Oct; 19(10):1759-64. PubMed ID: 18504251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
    Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
    Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.
    Rey-Búa B; Grande C; Sánchez Blanco JJ; Abrisqueta P; Gutiérrez A; Ramírez Páyer Á; Giné E; Zeberio Etxetxipia I; Terol MJ; de la Cruz Vicente F; Andreu R; Ramirez MJ; de la Fuente A; Viguria MC; Peñarrubia MJ; Jiménez-Ubieto A; Montes-Moreno S; López-Guillermo A; Caballero MD; Martín García-Sancho A
    Clin Cancer Res; 2024 Sep; 30(17):3704-3714. PubMed ID: 38900037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.